A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a reduction of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are most vulnerable to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the vaccine safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects roughly half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to generate defence proteins, which are then passed to the developing baby through the placenta. This mother-derived protection offers newborns with instant defence from the moment of birth, exactly when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson advises pregnant women to receive the vaccine at the recommended time, whilst noting that protection can still occur even if given later in the third trimester.
- Nearly 85 per cent protection when immunised 4 weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from day one
- Coverage possible with 2-week gap before early delivery
- Vaccination in the third trimester still offers significant protection for infants
Persuasive evidence from recent research
The efficacy of the pregnancy RSV vaccine has been established through a thorough investigation undertaken in England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This represents approximately 90 per cent of all births during that six-month period, providing comprehensive and reliable evidence of the vaccine’s actual performance. The study’s conclusions have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most critical early weeks. The scale of this research offers healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across diverse populations and circumstances.
The results reveal a compelling picture of the vaccine’s protective power. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction highlights the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions above 80 per cent represents a major public health success, potentially preventing thousands of infants from experiencing the distressing and potentially serious symptoms associated with severe RSV infection. These findings reinforce the importance of the vaccination programme established in the UK in 2024.
Study methodology and scope
The research examined birth and hospitalisation records from England over a six-month period, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The large sample size and comprehensive nature of the data collection ensured that findings were statistically significant and reflective of the wider population, rather than isolated cases or small subgroups.
The study specifically monitored hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for best possible protection, as well as to determine whether protection remained meaningful with briefer timeframes. The methodology measured actual clinical results rather than controlled laboratory conditions, providing tangible evidence of how the vaccine works when given across varied healthcare environments and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and its threats
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity varying dramatically from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during busier periods.
The infection causes inflammation deep within the lungs and airways, making it perilously hard for infected babies to feed and breathe adequately. Parents often witness their babies struggling visibly, their chests rising whilst they work to get enough air into their damaged lungs. Whilst the majority of babies improve through palliative treatment, a modest yet notable group succumb from respiratory syncytial virus complications annually, making immunisation programmes a critical public health priority for protecting the youngest and most vulnerable members of society.
- RSV causes inflammation in lungs, resulting in serious respiratory problems in babies
- Approximately half of newborns acquire the virus in their first few months of life
- Symptoms range from mild colds to serious chest infections that threaten life needing hospital treatment
- Over 20,000 UK babies require serious hospital care for RSV annually
- A small number of infants die from RSV related complications each year in the UK
Take-up rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women getting their jab at the optimal time for greatest protection. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, has stressed that timing matters greatly for ensuring newborns benefit from the most robust immunity from birth. Whilst the evidence indicates that vaccination performed at least four weeks prior to delivery provides nearly 85% protection, experts advise women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies via the placenta.
The communication from public health bodies remains clear: pregnant women should prioritise getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has reassured pregnant women that protection remains still achievable with reduced timeframes between vaccination and birth, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional differences in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and implementation timelines have varied across different regions and NHS trusts. Some areas have achieved higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and access to the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the national data demonstrates consistently strong protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to reach expectant mothers
- Regional disparities in vaccination coverage levels in different parts of England require targeted improvement
- Community health services modifying schemes to align with local requirements and situations
Practical implications and parental perspectives
The vaccine’s impressive effectiveness delivers concrete gains for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the introduction of this preventative solution, the 80% drop in admissions represents thousands of infants spared from severe infection. Parents no more face the upsetting situation of watching their newborns gasping for air or difficulty feeding, symptoms that mark serious RSV disease. The vaccine has substantially transformed the landscape of neonatal breathing health, providing expectant mothers a preventative option to protect their youngest infants during those vital initial period.
For families like that of Malachi, whose severe RSV infection caused profound brain damage, the vaccine’s availability carries profound emotional significance. His mother’s support of the jab highlights the transformative consequences that treatable infection can have on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story resonates strongly with parents now provided with protection. The knowledge that such serious complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has provided considerable reassurance to expectant mothers during their final trimester, converting what was once an predictable seasonal threat into a manageable risk.